Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease

Atherosclerosis

Volumn 193, Issue 1, 2007, Pages 168-176

  Schmitt, B ^a   Wolters, M ^a   Kressel, G ^a   Hulsmann O ^a   Strohle A ^a   Kuhn Velten W N ^b   Lichtinghagen, R ^c   Bub, A ^d   Barth, S W ^d   Stichtenoth, D O ^c   Hahn, A ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b Medizinisches Labor Bremen   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d FEDERAL RESEARCH INSTITUTE OF NUTRITION AND FOOD   (Germany)

Author keywords

Antioxidants; Asymmetric dimethylarginine; Folic acid; Homocysteine; Oxidized LDL

Indexed keywords

ALPHA CAROTENE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; COBALAMIN; FOLIC ACID; HOMOCYSTEINE; LYCOPENE; N(G),N(G) DIMETHYLARGININE; NICOTINIC ACID; POLYPHENOL; PYRIDOXINE; RIBOFLAVIN; SELENIUM; THIAMINE; UBIDECARENONE; VITAMIN B GROUP; ZINC;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VITAMIN SUPPLEMENTATION;

ADULT; AGED; ANTIOXIDANTS; ARGININE; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; VITAMIN B COMPLEX;

EID: 34249103968     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.06.007     Document Type: Article

References (57)

1. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20 (1992) S60-S62
2. Cooke J.P. Does ADMA cause endothelial dysfunction?. Arterioscler Thromb Vasc Biol 20 (2000) 2032-2037
3. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolaemia. Circulation 98 (1998) 1842-1847
4. Miyazaki H., Matsuoka H., Cooke J.P., et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99 (1999) 1141-1146
5. Valkonen V.P., Päivä H., Salonen J.T., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
6. Lu T.M., Ding Y.A., Charng M.J., and Lin S.J. Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol 26 (2003) 458-464
7. Yoo J.H., and Lee S.C. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 158 (2001) 425-430
8. Böger R.H., Bode-Böger S.M., Thiele W., et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95 (1997) 2068-2074
9. Usui M., Matsuoka H., Miyazaki H., et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62 (1998) 2425-2430
10. Chan J.R., Böger R.H., Bode-Böger S.M., et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 20 (2000) 1040-1046
11. Eid H.M., Eritsland J., Larsen J., Arnesen H., and Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166 (2003) 279-284
12. Lundman P., Eriksson M.J., Stühlinger M., et al. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38 (2001) 111-116
13. Surdacki A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999) 652-658
14. Goonasekera C.D., Shah V., Rees D.D., and Dillon M.J. Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma?. Blood Press 9 (2000) 16-21
15. Abbasi F., Asagmi T., Cooke J.P., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88 (2001) 1201-1203
16. Sydow K., Schwedhelm E., Arakawa N., et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of l-arginine and B vitamins. Cardiovasc Res 57 (2003) 244-252
17. Vallance P., and Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 24 (2004) 1023-1030
18. Kielstein J.T., and Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?. Am J Kidney Dis 46 (2005) 186-202
19. Böger R.H., and Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 4 (2003) 23-28
20. Osanai T., Saitoh M., Sasaki S., et al. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 42 (2003) 985-990
21. Böger R.H., Sydow K., Borlak J., et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87 (2000) 99-105
22. Böger R.H. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "l-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 134 (2004) 2842S-2847S
23. Tran C.T., Leiper J.M., and Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 4 (2003) 33-40
24. Fliser D. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule. Eur J Clin Invest 35 (2005) 71-79
25. MacAllister R.J., Parry H., Kimoto M., et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 119 (1996) 1533-1540
26. Ito A., Tsao P.S., Adimoolam S., et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99 (1999) 3092-3095
27. Stühlinger M.C., Tsao P.S., Her J.H., et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104 (2001) 2569-2575
28. Lin K.Y., Ito A., Asagami T., et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106 (2002) 987-992
29. Fairfield K.M., and Fletcher R.H. Vitamins for chronic disease prevention in adults. Scientific review. JAMA 287 (2002) 3116-3126
30. International Task Force for Prevention of Coronary Heart, Disease. Coronary heart disease: reducing the risk. Nutr Metab Cardiovasc Dis 8 (1998) 205-271
31. World Health Organization (WHO)/International Society of Hypertension (ISH). Guidelines Subcommittee 1. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17 (1999) 151-183
32. Cifkova R., et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 21 (2003) 1779-1786
33. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diab Care 28 (2005) S37-S42
34. World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Part I. The problem of overweight and obesity. Genf: WHO Technical Report Series 894; 2000.
35. Kirchherr H., and Kühn-Velten W.N. HPLC-tandem mass spectrometric method for rapid quantification of dimethylarginines in human plasma. Clin Chem 51 (2005) 249-252
36. Kimura M., Kanehira K., and Yokoi K. Highly sensitive and simple liquid chromatographic determination in plasma of B6 vitamers, especially pyridoxal 5′-phosphate. J Chromatogr A 722 (1996) 295-301
37. Holvoet P., Vanhaecke J., Janssens F., Van de Werf F., and Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98 (1998) 1487-1494
38. Catignani G.L., and Bieri J.G. Simultaneous determination of retinol and alpha-tocopherol in serum or plasma by liquid chromatography. Clin Chem 29 (1983) 708-712
39. Re R., Pellegrini N., Proteggente A., et al. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 26 (1999) 1231-1237
40. Boyd S., Owens D., Gin T., et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 85 (2001) 1313-1315
41. Ueland P.M., Refsum H., Beresford S.A., and Vollset S.E. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72 (2000) 324-332
42. Wald D.S., Law M., and Morris J.K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325 (2002) 1202
43. Lentz S.R. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 3 (2005) 1646-1654
44. Lentz S.R., Rodionov R.N., and Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atheroscler Suppl 4 (2003) 61-65
45. Böger R.H., Bode-Böger S.M., Sydow K., Heistad D.D., and Lentz S.R. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 20 (2000) 1557-1564
46. Böger R.H., Lentz S.R., Bode-Böger S.M., Knapp H.R., and Haynes W.G. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci 100 (2001) 161-167
47. Stühlinger M.C., Oka R.K., Graf E.E., et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 108 (2003) 933-938
48. Holven K.B., Aukrust P., Holm T., Ose L., and Nenseter M.S. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler Thromb Vasc Biol 22 (2003) 699-703
49. Jonasson T.F., Hedner T., Hultberg B., and Ohlin H. Hyperhomocysteinaemia is not associated with increased levels of asymmetric dimethylarginine in patients with ischaemic heart disease. Eur J Clin Invest 33 (2003) 543-549
50. Ziegler S., Mittermayer F., Plank C., et al. Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease. J Clin Endocrinol Metab 90 (2005) 2175-2178
51. Eid H.M., Arnesen H., Hjerkinn E.M., Lyberg T., and Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 53 (2004) 1574-1579
52. Post M.S., Verhoeven M.O., van der Mooren M.J., et al. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 88 (2003) 4221-4226
53. Valkonen V.P., Laakso J., Paiva H., et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?. Atheroscler Suppl 4 (2003) 19-22
54. Dierkes J., Westphal S., Martens-Lobenhoffer J., Luley C., and Bode-Böger S.M. Fenofibrate increases the l-arginine:ADMA ratio by increase of l-arginine concentration but has no effect on ADMA concentration. Atherosclerosis 173 (2004) 239-244
55. Siroka R., Trefil L., Rajdl D., et al. Asymmetric dimethylarginine, homocysteine and renal function-is there a relation?. Clin Chem Lab Med 43 (2005) 1147-1150
56. Schulze F., Maas R., Freese R., et al. Determination of a reference value for N(G), N(G)-dimethyl-l-arginine in 500 subjects. Eur J Clin Invest 35 (2005) 622-626
57. Paroni R., Fermo I., Fiorina P., and Cighetti G. Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects. Amino Acids 28 (2005) 389-394